{{Rsnum
|rsid=179943
|Gene=ATXN1
|Chromosome=6
|position=16398087
|Orientation=minus
|GMAF=0.1951
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ATXN1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 89.3 | 8.0 | 2.7
| HCB | 43.1 | 38.0 | 19.0
| JPT | 36.3 | 46.0 | 17.7
| YRI | 66.7 | 32.0 | 1.4
| ASW | 68.4 | 31.6 | 0.0
| CHB | 43.1 | 38.0 | 19.0
| CHD | 40.4 | 50.5 | 9.2
| GIH | 69.3 | 29.7 | 1.0
| LWK | 66.4 | 30.0 | 3.6
| MEX | 67.2 | 31.0 | 1.7
| MKK | 64.7 | 32.1 | 3.2
| TSI | 86.1 | 13.9 | 0.0
| HapMapRevision=28
}}

[http://www.genomeweb.com/issues/news/150344-1.html genomeweb] [[rs4420638]] [[rs11159647]] and [[rs3826656]] were also significantly associated with [[Alzheimer’s disease]]

{{PharmGKB
|RSID=rs179943
|Name_s=
|Gene_s=ATXN1
|Feature=
|Evidence=PubMed ID:18976728
|Annotation=In a GWAS of Alzheimer Disease families of self-reported European ancestry, this SNP was found to be associated with Alzheimer Disease. This association did not reach significance in replication attempts with three other family samples.
|Drugs=
|Drug Classes=
|Diseases=Alzheimer Disease
|Curation Level=Curated
|PharmGKB Accession ID=PA162356253
}}

{{PMID Auto
|PMID=20308783
|Title=Follow-up study of susceptibility Loci for Alzheimer's disease and onset age identified by genome-wide association
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs179943
|overall_frequency_n=18
|overall_frequency_d=128
|overall_frequency=0.140625
|n_genomes=13
|n_genomes_annotated=0
|n_haplomes=14
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}